Tibet Rhodiola Pharmaceutical Holdings invests RMB351m in Stemirna Therapeutics

Tibet Rhodiola Pharmaceutical Holdings issued an announcement that by paying the cooperative consideration of the Covid-19 vaccine product, tuberculosis vaccine and influenza vaccine product to Stemirna Therapeutics, the company has obtained the exclusive worldwide development, registration, production, use and commercialization rights of the above products.

Tibet Rhodiola Pharmaceutical Holdings issued an announcement that by paying the cooperative consideration of the Covid-19 vaccine product, tuberculosis vaccine and influenza vaccine product to Stemirna Therapeutics, the company has obtained the exclusive worldwide development, registration, production, use and commercialization rights of the above products.

According to the announcement, based on their respective advantageous capabilities and strategic resources, the two parties have entered into an exclusive global strategic partnership. According to the research and development progress of the Covid-19 vaccine, tuberculosis vaccine and influenza vaccine, Tibet Rhodiola Pharmaceutical Holdings will invest 351 million yuan in Stemirna Therapeutics in stages, and obtain the global exclusive authorization of the above vaccines.

Established in May 2016, Stemirna Therapeutics is a company dedicated to building a precision cancer immunotherapy technology platform. The company’s core competitiveness lies in mRNA synthesis platform and LPP nano delivery platform.

Since its inception, Stemirna has built a 50-strong R&D and medical team, has a 3,000-square-meter research and development site, including a nearly 400-square-meter GMP production facility, and has established the first mature mRNA vaccine production line in China.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/21/tibet-rhodiola-pharmaceutical-holdings-invests-rmb351m-in-stemirna-therapeutics/.

Leave a Reply

Please Login to Comment